Gilead’s Q1 shows HIV momentum remains powerful, but diversification is still unfinished
Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.
AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV
AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV. Explore what the Phase 3 data mean for regulation and practice.
ViiV Healthcare’s Cabenuva and Dovato strategy looks like an ecosystem play as ultra long-acting candidates advance
ViiV Healthcare heads to CROI 2026 with ultra long-acting HIV data for VH4524184, VH4011499 and more. See what it changes next.